Simon Kerry

Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium.

Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom.

Isogenica Ltd. provides research and development services in the fields of new peptide, antibody and other polypeptide drug candidates. It offers llamdA System, Xab System and 4D Fab System. The company was founded by Kevin Fitzgerald in 2000 and is headquartered in Little Chesterford, the United Kingdom.

Part of Active Biotech AB, Actinova Ltd. is a British company that provides research and development services to the biotechnology sectors and also develops drugs and vaccines. The company is based in Cambridge, UK.

Actigen Ltd. provides biological products. The private company is based in Cambridge, UK.

Argonaut Therapeutics Ltd. develops novel epigenetic therapies. It targets abnormal arginine methylation in cancer. The company was founded by Nicholas La Thangue and is headquartered in Oxford, the United Kingdom.

Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.